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Streptococcus pneumoniae remains one of the major pathogens
in children and adults worldwide. In addition to the
100 000 000 ear infections in children, it is estimated that it
is responsible for more than 5 000 000 pneumonia cases and
approximately 100 000 meningitis cases, the whole being
associated with 10 000 000 bacteraemia cases every year.
Mortality is still considerable, despite a wide battery of anti-
biotics. The ability of this bacterium to cause invasive disease
is linked to multiple virulence factors, described in detail in
the review by Mitchell and Mitchell. In addition to its capsule,
an essential factor for virulence that allows the bacteria to
escape opsonization–phagocytosis, many surface proteins
enable it to colonize and adhere to the nasopharyngeal and
respiratory tract epithelium. Among these, we must mention
the choline-binding proteins and divalent metal ion-binding
lipoproteins, some of which behave as adhesins, different
exoglycosidases, such as the neuraminidase, which facilitates
access to cell receptors, the autolysins, leading to lysis and
releasing cell wall bacterial constituents, and different intra-
cellular proteins, among which is pneumolysin. Combined
with major inflammatory reactions, all of these factors, which
impede the ciliary dynamic, facilitate access and adhesion of
pneumococci to the pulmonary epithelium.
Some of the virulence factors (pneumolysin, choline-bind-
ing proteins, etc.), by mechanisms still not well understood,
will facilitate access to the circulation after breaching of the
epithelium and enable the bacterium to reach other loca-
tions. All of these pathologies, which are particularly com-
mon at the extremes of life, can be explained, in part, by
immaturity of the immune system before the age of 2 years
and a decline in the immune response in the elderly. Not
only humoral but also cellular immunity plays an important
role in the fight against invasive infections, and well-defined
deficiencies in innate or acquired immunity are factors con-
ducive to their occurrence. If the 91 serotypes of pneumo-
cocci are distributed unevenly according to age and country,
they contribute, despite the progress in vaccination, by their
great numbers and their evolution in successive waves, to
the maintenance of pneumococci in the population. In this
context, the introduction of the conjugate vaccine, which
includes a limited number of serotypes, has reduced not only
the incidence of invasive infections, but also pneumococcal
carriage in vaccinated children, resulting in herd immunity
that decreases the frequency of pneumococcal disease in
those age groups that are not receiving the vaccine; but the
drawback is the rapid serotype replacement, requiring con-
stant changes to its formulation.
At present, the search for a universal pneumococcal vac-
cine covering all serotypes, using different associations of
conserved proteins, remains in its infancy. In fact, we do not
know what would be the result of complete eradication of
S. pneumoniae from the human nasopharynx. Should we fear
replacement by other pathogens, which could possibly be
favoured by the loss of related species such as Streptococcus
mitis? Should the ideal vaccine strategy not, rather, seek to
protect only against certain clonal complexes that remain to
be defined?
All of this would be less of a problem in the absence of anti-
biotic resistance; however, as described in the review by
Lin˜ares et al., constant antibiotic pressure and the ability of
pneumococci, through transformation, to incorporate DNA of
other pneumococci or closely related species, such as oral
streptococci, are the major contributors to the acquisition and
evolution of resistance traits.
Thus, epidemiological surveillance of the serotype distribu-
tion and of antibiotic resistance remains the major strategy
for the design of future vaccines and for the optimal adapta-
tion of empirical therapy.
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